S.2099 - Restore Prescription Drugs Discount Act (119th Congress)
Summary
S.2099, the Restore Prescription Drugs Discount Act, proposes to repeal the Robinson-Patman Act of 1936. This act currently prohibits certain forms of price discrimination, particularly in the sale of goods. The bill's short title suggests a focus on prescription drug pricing.
Expected Effects
The repeal of the Robinson-Patman Act could lead to significant changes in pricing strategies across various industries, especially pharmaceuticals. It may result in more aggressive price competition or, conversely, allow larger companies to leverage their market power. This could affect both consumers and smaller businesses.
Potential Benefits
- Potentially lower prescription drug prices due to increased competition.
- Greater pricing flexibility for businesses.
- Reduced regulatory burden on companies.
- Stimulation of innovation in pricing strategies.
- Possible efficiency gains in the distribution of goods.
Potential Disadvantages
- Potential for predatory pricing by large corporations, harming smaller businesses.
- Increased price discrimination against certain consumer groups.
- Possible instability in the pharmaceutical market.
- Job losses in smaller businesses unable to compete with larger companies.
- Reduced consumer protection against unfair pricing practices.
Most Disadvantaged Areas:
Constitutional Alignment
The bill falls under the Commerce Clause (Article I, Section 8, Clause 3) of the U.S. Constitution, which grants Congress the power to regulate interstate commerce. Repealing a law that regulates commerce is within the purview of congressional authority. The bill does not appear to infringe on any individual rights or liberties protected by the Constitution or its amendments.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).